Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial
Source: View publication →
A large phase 3 trial demonstrated that a single administration of faecal microbiota transplantation via rectal enema provided no clinical benefit over an autologous placebo in patients with moderate-to-severe irritable bowel syndrome.
Key Findings
Study Design
Study Limitations
Clinical Significance
The REFIT2 trial provides robust, definitive evidence refuting the efficacy of single-dose faecal microbiota transplantation (FMT) via enema for irritable bowel syndrome (IBS). These negative findings suggest that single-intervention microbiota modulation alone is insufficient to manage the complex pathophysiology of IBS, heavily dampening clinical enthusiasm for using FMT as a standard therapeutic option for these patients.
Historical Context
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder, and accumulating data over the past decade heavily implicated the gut microbiome in its pathogenesis. Previous, smaller trials of FMT for IBS produced conflicting results—some suggested striking clinical remission (such as the smaller REFIT1 trial or trials using super-donors), while others showed no benefit over placebo. REFIT2 was designed as a definitive, multi-center, phase 3 trial to answer the question using a rigorous autologous placebo control. Its definitively negative results mark a significant pivot in the field, challenging the previously optimistic trajectory of microbiome-modulating therapies for functional bowel disorders.
Guided Discussion
High-yield insights from every perspective
How does the use of an autologous placebo in the REFIT2 trial help researchers isolate the true therapeutic effect of a healthy donor's microbiome in IBS compared to using a standard saline enema?
Key Response
Using the patient's own stool (autologous FMT) controls for the procedural effects (bowel prep, enema administration) and the psychological placebo effect, ensuring any benefit seen in the treatment group is solely due to the introduction of a novel, healthy donor microbiome rather than the mechanical or psychological process itself.
A patient with severe IBS-D brings you an article about the microbiome and requests an FMT referral. Based on the REFIT2 trial and current standard of care, how should you counsel this patient regarding their request and alternative evidence-based therapies?
Key Response
Residents must practice translating evidence into patient counseling. The REFIT2 trial provides robust phase 3 evidence that FMT via enema offers no clinical benefit for IBS. Counseling should validate the patient's interest in the gut-brain axis while redirecting them toward proven treatments like dietary modifications (low FODMAP), gut-directed psychotherapies, or targeted pharmacotherapy (e.g., eluxadoline, rifaximin).
Previous smaller, positive FMT trials in IBS often used oral capsules, repeated dosing, or highly specific 'super-donors' implanted via colonoscopy, while REFIT2 used a single rectal enema. How might these differences in route of administration, frequency, and donor matching explain the discordant outcomes in FMT IBS literature?
Key Response
Fellows need to synthesize conflicting literature. A single enema only reaches the distal colon, whereas oral capsules or upper GI delivery impact the small intestine where much of IBS pathophysiology (like SIBO or altered motility) might originate. Furthermore, IBS may require continuous microbiome modification rather than a single engraftment attempt, highlighting the nuance in FMT delivery mechanisms.
The microbiome has been heavily marketed as a panacea for functional GI disorders. How does a definitive negative phase 3 trial like REFIT2 change the way we teach trainees about the limitations of translational microbiome research, and how does it reshape our approach to the massive 'placebo response' in functional disorders?
Key Response
Attendings must contextualize negative data. This trial highlights that despite strong preclinical rationale linking dysbiosis to IBS, macroscopic microbiome replacement fails. It emphasizes teaching trainees that functional GI disorders have a notoriously high placebo response rate, which necessitates rigorous trial designs (like autologous FMT) before adopting highly publicized, biologically plausible therapies.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
IBS is a highly heterogeneous disorder with distinct subtypes (IBS-C, IBS-D, IBS-M) and overlapping pathophysiologies (visceral hypersensitivity, altered motility, gut-brain dysregulation). From a methodological standpoint, how does enrolling a broad moderate-to-severe IBS population in a phase 3 trial like REFIT2 risk washing out a true, subtype-specific microbiome therapeutic signal?
Key Response
Researchers must consider phenotype-microbiome interactions. Grouping all IBS subtypes together assumes a uniform microbial deficit. If FMT only works for post-infectious IBS or specific dysbiosis-driven IBS-D, analyzing them as a single monolithic cohort increases type II error, potentially masking a significant effect in a specific endotype.
Publishing a negative trial in a premier journal like The Lancet is a deliberate editorial choice. What specific methodological strengths of the REFIT2 trial, such as its choice of placebo, blinding integrity, and choice of primary endpoint, elevate it above previous negative studies to warrant high-impact publication?
Key Response
Editors value rigorous methodology that definitively answers a controversial clinical question. REFIT2's use of an autologous placebo is a gold-standard control that effectively eliminates the massive placebo response seen in functional GI trials. A definitive, well-powered negative trial prevents futile interventions from entering practice, making it highly impactful despite the negative result.
Current ACG and AGA guidelines strongly recommend against the use of FMT for IBS outside of clinical trials, based primarily on low-to-moderate quality, conflicting phase 2 data. How does the addition of the REFIT2 phase 3 data impact the strength of this recommendation and the overall quality of evidence supporting it in future iterations?
Key Response
Guideline committees use GRADE methodology. REFIT2 provides high-quality, large-scale, phase 3 data confirming the lack of efficacy. This allows the committee to upgrade the level of evidence from 'low/moderate' to 'high', cementing a 'strong recommendation against' FMT for IBS, thereby protecting patients from unproven, costly, and potentially risky off-label procedures.
Clinical Landscape
Noteworthy Related Trials
Johnsen FMT IBS Trial
Tested
FMT via colonoscopy
Population
Patients with moderate-to-severe IBS
Comparator
Autologous FMT via colonoscopy
Endpoint
Reduction of greater than 75 points in IBS-SSS at 3 months
El-Salhy FMT IBS Trial
Tested
FMT (30g or 60g) from a super-donor via gastroscope
Population
Patients with moderate-to-severe IBS
Comparator
Autologous FMT (placebo)
Endpoint
Reduction of at least 50 points in IBS-SSS at 3 months
Aroniadis FMT IBS-D Trial
Tested
FMT via oral capsules
Population
Patients with diarrhea-predominant IBS
Comparator
Placebo capsules
Endpoint
IBS-SSS symptom reduction at 12 weeks
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis